Can a new eye injection beat the current standard for diabetic vision loss?
NCT ID NCT07734844
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 3 trial compares an experimental drug, tabirafusp tedromer, against the standard treatment aflibercept for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 910 adults with DME will receive injections into the eye and be followed for one year to see which treatment better improves eyesight. The study aims to determine whether the new drug offers a more effective option for managing this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called tabirafusp tedromer (also known as KSI-501), given as an injection into the eye
- What this could lead to
- If it works, this could offer a new treatment option for diabetic macular edema, potentially improving vision better than current standard therapy.
- What could go wrong
- This is an early-phase 3 trial, so the experimental drug may not prove superior to aflibercept. Eye injections carry risks like infection, inflammation, or increased eye pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy
- New hope for diabetes-related vision loss: experimental drug faces final test